Yale Medicine

Yale Medicine is a news site focused on providing information about the latest developments in medical research and treatments. The site covers a wide range of topics, including new coronavirus strains, rising rates of early-onset cancer, and new medications for cardiovascular diseases. The articles provided are mostly neutral and do not show any clear bias. There is a mention of collaborations with pharmaceutical companies for clinical trials and research, but no clear conflicts of interest are identified. The site's content is generally easy to read and understand.

84%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This news site has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on its reporting.

Bias

95%

Examples:

  • The articles provided are mostly neutral and do not show any clear bias.

Conflicts of Interest

75%

Examples:

  • There is a mention of collaborations with pharmaceutical companies for clinical trials and research, but no clear conflicts of interest are identified.

Contradictions

88%

Examples:

  • In one article, it was stated that early-onset cancers are diagnosed in adults between the ages of 18 and 49, while another source mentions breast cancer, tracheal, bronchus and lung cancer, stomach and colorectal cancers as the deadliest cancers in younger people. These two statements contradict each other.

Deceptions

80%

Examples:

  • In one article, it was mentioned that in the early spring of 2024, COVID-19 cases were down. This statement could be interpreted as deceptive if taken out of context.

Recent Articles

  • New Covid FLiRT Variants: Dominant Strains in US and Europe, Potential Impact on Vaccine Effectiveness

    New Covid FLiRT Variants: Dominant Strains in US and Europe, Potential Impact on Vaccine Effectiveness

    Broke On: Wednesday, 22 May 2024 New Covid FLiRT Variants, KP.2 and KP.1.1, account for over 35% of US Covid-19 cases as of May 2024, surpassing the previously dominant JN.1 strain with similar mutations. These new variants have spread to Europe but currently cause no more severe disease than previous strains, although they may evade immunity from vaccines or past infections. Health officials closely monitor their spread and assess vaccine effectiveness against them.
  • Early-Onset Cancers: Alarming Increase in Cancer Cases Among Younger Individuals - Prevention and Risk Factors

    Early-Onset Cancers: Alarming Increase in Cancer Cases Among Younger Individuals - Prevention and Risk Factors

    Broke On: Thursday, 18 April 2024 A rise in early-onset cancers among younger individuals, driven by factors like obesity, sedentary lifestyles, and environmental carcinogens, has shifted cancer demographics. Preventive measures include regular screenings, reducing processed food intake, maintaining a healthy weight, engaging in physical activity, managing stress levels and being aware of family history.
  • Wegovy Approved to Reduce Heart Complications in Overweight People with Cardiovascular Disease by 20%

    Wegovy Approved to Reduce Heart Complications in Overweight People with Cardiovascular Disease by 20%

    Broke On: Monday, 18 March 2024 Wegovy, a weight loss drug approved by the FDA for reducing cardiovascular risks in overweight people with heart disease, is now being used to reduce the risk of major heart complications including heart attack, stroke or cardiovascular-related deaths. The new label expansion for Wegovy indicates that it can be used to reduce these risks by 20% in this population. This approval opens up a new market for weight loss drugs and could greatly expand older adults' access to treatments that so far have been limited.